GPT and Hepatic steatosis: The interim analysis results of a 52-week phase 2b RCT of seladelpar (10–50 mg/d) found it to reduce ALT, GGT, and ALP levels, but only minimally influence liver steatosis at 12 weeks of treatment [103].